6 January 2020

Drug shortage update: Cyclopentolate 1% and 0.5% minims

We have become aware of a temporary shortage of cyclopentolate minims.

Bausch and Lomb, the manufacturer, said the supply disruption is due to a shortage of the active pharmaceutical ingredient and more should become available mid to late January. 

If you have run out of supplies, you may enquire whether other practices near to you have surplus stock that they could supply you to tide you over the next couple of weeks. Alternatively, for low-risk cases, you may wish to consider postponing the cycloplegic refraction for a couple of weeks, reserving your stocks for children at a higher risk of a deviation or amblyopia. Where a cycloplegic refraction is indicated, you should ensure it takes place, but use your professional judgement to determine the best way to achieve this. 

The Royal College of Ophthalmologists issued the following advice: 

Use multi-dose preserved cyclopentolate eye drops where appropriate. If this is not appropriate, consider tropicamide 1% or phenylephrine 2.5% but be aware that phenylephrine 2.5% is also in short supply.

Consider atropine 1% if there is no other safe alternative. Cyclopentolate hydrochloride must be reserved for cycloplegic refraction. 


Related further reading

Claire Moulds examines the impact of a power of attorney on the patient relationship.

A message from Leon Davies, College President

Research, including work carried out in high-street optometry practices, is driving innovation in clinical practice and at a policy level, writes Mark Gould.